Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JANX011 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Dosage per cohort will increase to determine the maximum tolerable dose. |
| Name | Type | Description |
|---|---|---|
| JANX011 | DRUG | JANX011 is administered subcutaneously, one time. |
Inclusion Criteria: * Healthy men and women, in the opinion of the PI or designee and as determined by physical examination, laboratory screening tests, and medical history. * Aged 18 to 65 years, with a body weight between 50 to 120 kg and a body mass index (BMI) between 18 to 32 kg/m2 (all inclus...
JANX011 is an investigational small molecule being developed for autoimmune conditions. It is currently in early Phase 1 clinical development, with a study enrolling healthy adult volunteers to assess its safety and tolerability. The drug is not yet approved and remains in clinical testing.
JANX011 targets CD19, a protein found on B cells. By targeting CD19, the drug is designed to modulate B-cell activity, which is relevant to autoimmune diseases. This mechanism is being evaluated in early clinical trials to understand its safety and tolerability.
JANX011 is being developed by Janux Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol JANX. The company is conducting a Phase 1 clinical trial of JANX011 in healthy volunteers to assess the drug's safety and tolerability.
JANX011 is in Phase 1 clinical development. The ongoing trial, NCT07291323, is an early Phase 1 study that is currently recruiting participants. The drug is investigational and has not been approved by regulatory authorities.
JANX011 is being studied in one clinical trial, NCT07291323, titled 'Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.' This early Phase 1 study is recruiting 60 healthy volunteers in Australia and is not randomized or blinded.